ACEA (arachidonyl-2-chloroethylamide), the selective cannabinoid CB1 receptor agonist, protects against aspirin-induced gastric ulceration.
The effect of a selective cannabinoid CB1 receptor agonist, ACEA (arachidonyl-2-chloroethylamide) in an aspirin-induced ulcer model was studied in rats. ACEA (1.25-5 mg/kg i.p.) significantly reduced gastric ulcer formation to 24, 21 and 0.6% respectively. These results confirm the cytoprotective effect of CB1 receptor agonists and suggest that the endocannabinoid system might be the target for a novel class of anti-ulcer drugs.